NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

Share this content:
NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF
NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

TUESDAY, Aug. 22, 2017 (HealthDay News) -- For high-risk patients with heart failure and reduced ejection fraction (HFrEF), an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy does not improve clinical outcomes versus usual care, according to a study published in the Aug. 22/29 issue of the Journal of the American Medical Association.

G. Michael Felker, M.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues randomized patients to an NT-proBNP-guided strategy, in which heart failure therapy was titrated with the goal of achieving a target NT-proBNP of less than 1,000 pg/mL (446 patients), or usual care (448 patients who received heart failure care in accordance with published guidelines).

The study was stopped for futility when 894 of the planned 1,100 patients had been enrolled with follow-up for a median of 15 months. The researchers found that the primary end point of composite of time-to-first heart failure hospitalization or cardiovascular mortality occurred in 37 percent of both the biomarker-guided and usual-care groups (adjusted hazard ratio, 0.98; 95 percent confidence interval, 0.79 to 1.22; P = 0.88). Cardiovascular mortality was 12 and 13 percent in the biomarker-guided and usual-care groups (hazard ratio, 0.94; 95 percent confidence interval, 0.65 to 1.37; P = 0.75). There was no significant difference between the groups in secondary end points or the decreases in NT-proBNP levels achieved.

"In high-risk patients with HFrEF, a strategy of NT-proBNP-guided therapy was not more effective than a usual care strategy in improving outcomes," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »